Background/Aims: Colonoscopy screening has been accepted broadly to evaluate the risk and incidence of colorectal cancer (CRC) during health examination in outpatients. However, the intrusiveness, complexity and discomfort of colonoscopy may limit its application and the compliance of patients. Thus, more reliable and convenient diagnostic methods are necessary for CRC screening. Genome instability, especially copy-number variation (CNV), is a hallmark of cancer and has been proved to have potential in clinical application. Methods: We determined the diagnostic potential of chromosomal CNV at the arm level by wholegenome sequencing of CRC plasma samples (n = 32) and healthy controls (n = 38). Arm level CNV was determined and the consistence of arm-level CNV between plasma and tissue was further analyzed. Two methods including regular z score and trained Support Vector Machine (SVM) classifier were applied for detection of colorectal cancer. Results: In plasma samples of CRC patients, the most frequent deletions were detected on chromosomes 6, 8p, 14q and 1p, and the most frequent amplifications occurred on chromosome 19, 5, 2, 9p and 20p. These arm-level alterations detected in plasma were also observed in tumor tissues. We showed that the specificity of regular z score analysis for the detection of colorectal cancer was 86.8% (33/38), whereas its sensitivity was only 56.3% (18/32). Applying a trained SVM classifier (n = 40 in trained group) as the standard to detect colorectal cancer relevance ratio in the test samples (n = 30), a sensitivity of 91.7% (11/12) and a specificity 88.9% (16/18) were finally reached. Furthermore, all five early CRC patients in stages I and II were successfully detected. Conclusion: Trained SVM classifier based on arm-level CNVs can be used as a promising method to screen early-stage CRC.
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Introduction
Colorectal cancer is the commonly diagnosed cancer worldwide, ranking third in male and second in female and giving rise to an estimated 1.4 million cases and 693, 900 deaths in 2012 [1] . Decreases in both the incidence and mortality of CRC have been observed in some developed countries, mostly due to the increased screening rate and a reduced prevalence of risk factors [2, 3] . However, the mortality rate is still increasing in developing countries, including China, Russia and Brazil [4] [5] [6] .
The existing screening methods for CRC include colonoscopy, Fecal Immunochemical Test (FIT) [7] , multi-target stool DNA testing (Cologuard) [8] and methylated septin9 assay [9] . Among all the screening methods colonoscopy screening appears to have gained acceptance among healthcare professionals and patients. However, intrusiveness and complexity may limit its use as a primary screening modality and cannot address the increasing number of at-risk individuals in practice. FIT, Cologuard and Septin9 assay give non-invasive methods to detect colorectal cancer. The sensitivity for CRC detection was 92.3% for Cologuard, 73.8% for FIT and 73.3% for Septin9, with specificity at 89.8%，96.4% and 81.5%, respectively. However, the sensitivity for detecting early CRC was only 57% for Septin9 [10] and 70% for FIT [8] . Hence，more reliable and convenient screening methods are needed for early CRC's detection.
Almost all cancer types exhibit chromosomal structural instability and copy number variations (CNV) are extremely common in cancer [11, 12] . Recent studies have explored the utility of copy number variations presenting in cell-free DNA (cfDNA) fragments in serum/ plasma as a potential clinically useful biomarker to detect prostate cancer, giving a diagnostic accuracy of 83% [13] . With the whole-genome analyses of cfDNA, Leary, et al. identified chromosomal alterations present in all plasma of advanced-stage cancer patients [12] . Jiang,et al. used massively parallel sequencing and chromosome arm-level z score analysis (CAZA) to detect chromosomal arm-level CNVs on the chromosomes 1 and 8 in plasma of hepatocellular carcinoma, revealed that 84.4% of patients had at least one arm-level CNV in plasma, while healthy controls and HBV carriers without cancer showed little CNV [14] . These results suggest that CNV in plasma might be the potential tumor biomarker with high sensitivity and specificity.
Given the universal nature of chromosomal alterations in human cancer and improved methods for detecting these changes, we questioned whether we could directly identify chromosomal alterations in plasma to screen early CRC with acceptable cost. Here, we analyzed the CNVs in cfDNA from CRC patients to evaluate the sensitivity and specificity with regular z score and trained SVM classifier methods.
Materials and Methods

Patient Recruitment
Volunteers undergoing gastrointestinal endoscopy examination were recruited and well informed at the PLA Army General Hospital between March 2013 and August 2015. The criteria for the healthy control groups included: (1) self-reported absence of existing or previous cancer symptoms; (2) negative results of gastrointestinal endoscopy examination for colorectal polyps or tumor. CRC was confirmed and clinical stages were classified by further pathologic analysis of endoscopic biopsy samples.
DNA extraction, library preparation and sequencing
After collection into EDTA-containing tubes, peripheral blood samples were centrifuged at 1, 600×g and subsequently 16, 000×g for 10 min at 4 °C within 6 hours to obtain clear cell-free plasma. The paired tumor tissue sections were also obtained from Pathology department of PLA Army General Hospital. Plasma DNA was isolated from 1 mL of plasma and tumor DNA was extracted from 5 FFPE tissues using magnetic beads and quantified using Qubit 2.0 (Life Technology). All the samples selected for whole-genome library construction were prepared using a DNA NGS Library Preparation Kit (ScreenDx) following the 
Mapping of sequencing data
After base calling and data filtration, the sequencing data for each sample were separated from the raw lane data according to the corresponding eight-base index sequences. The first single-end reads were then aligned to the non-repeat-masked human reference genome (NCBI build37/hg19) using BWA with two mismatches allowed to identify reads that mapped to a unique genomic location for further analysis.
Copy number variation detection
Copy number changes derived from tumor cells can be detected in plasma at advanced clinical stage via z score analysis [12] . To determine if z score could be adopted in our datasets, we calculated z score of all chromosome arms in 70 plasma samples as reported previously [14] . Briefly, we divided the reference genome into 100-kb windows and determined the read counts that fell into each 100-kb window. Then, the number of read counts for each arm was calculated by summing the values of all of the 100-kb windows on the chromosome arm after GC correction. Finally, the z score represented a significantly increased chromosome arm (z score > 2.96) or significantly decreased chromosome arm (z score < -2.96) compared with healthy controls.
Distribution feature analysis of chromosome CNVs at the arm level
Copy number amplifications and deletions in each chromosome were calculated for CRC patients. A heat map of unsupervised clustering of z score of each chromosome arm from both healthy individuals and CRC patients was drawn. Comparison of arm-level CNV both in plasma and tumor tissues were also analyzed. All steps were implemented in R.
Support vector machine classifier
The SVM algorithm was used by implementing the e1071 R package for the classification of CRC and healthy individuals. SVM is a supervised learning algorithm for two-group classification with the considerable advantages of average classification accuracy and time cost in the training process [15, 16] . Considering a small sample size, a linear kernel was applied in SVM modelling, and leave-one-out cross was also carried out for validation. Decision value can be calculated by w*x + b, where coefficient "w" and offset "b" are determined in SVM, and "x" is the z score of subjects on chromosome arm level. Of the total 70 sequenced samples, 40 samples were randomly selected for the training set (20 CRC samples and 20 healthy samples), and the remaining samples were used as the test set. Linear kernel was used with cost optimized prior to model training. The receiver operating characteristic curve (ROC) was generated using the ROC R package to evaluate the model performance. Regular z score analysis to detect aneuploidy in plasma Z score algorithm was regularly chosen for detection of copy number variations when using next generation sequencing technology [12, 17, 18] . Given that the most prevalent CNVs across the entire genome are either very short (focal) or almost exactly the length of a chromosome arm (armlevel) and arm-level CNVs occur approximately 30 times more frequently than focal CNVs [11] , we chose to detect arm-level CNV on at least one chromosome arm in plasma as the symbol of cancer happening. The other reason of analysis of arm-level CNVs was that the larger chromosome region was chosen the less sequencing data was needed at a given confidence level [19] . By defining an absolute value of the 
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Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry z score of 2.96 as the threshold for robust copy number variation, we found that 33 healthy controls were negative for arm-level CNV and that the remaining five were positive. However, only 18 samples in the CRC group had CNVs on at least one chromosome arm, and CNVs failed to be detected in the remaining patient group (14/32) (Fig. 2 ) . In total, we showed that the specificity of z score analysis for the detection of arm-level CNV in plasma was 86.8%, whereas its sensitivity was only 56.3% ( 
Analysis of copy number alteration distribution on chromosome arms
Previous studies indicated that colorectal cancer had tissue-specific copy number variations and arm-level hotspot regions [20, 21] , we also noticed this trend in Fig. 2that chromosome 2q, 9p and 19q tended to gain while chromosome 6q, 8p and 14q tended to loss. To further explore molecular CNV features in cfDNA of CRC, we analyzed the prevalence of specific arm-level CNV in all 18 patients with arm-level alterations by counting the number of samples containing alterations at the arm level of each chromosome (excluding the short arm of the acrocentric chromosome 22, X and Y) (Fig. 3 ). Deletions were detected most frequently on chromosomes 14q (8/18), 6q (6/18), 1p (5/18), 6p (5/18), 8p (8/18), 3p (4/18),7q (4/18), 12p (4/18), 12q (4/18), 14p (4/18), 16p (4/18), and amplifications were most frequent on chromosomes 9p (9/18), 19q (9/18), 2q (6/19), 5p (6/19), 5q (6/19), 2p (5/18), 9p (5/18), 19p (5/18), 20p (5/18). These results were partly consistent with other study [21] . Thus, the occurrence frequency of alterations in different chromosomes varies among different samples.
To further confirm the reliability of our method, we identified whether previous reported [22] could also be detected in our samples. We analyzed copy number variations of every 100kb window on chromosome and counted the alteration frequency of each window among all CRC samples. Our results showed that SKP2, MYC, MDM4 and MYCN had high frequency of amplification while CDKN2C tend to deletion in plasma of CRC patients (Fig. 4) length. After sequencing all the data were analyzed to identify arm-level CNVs as same as the plasma sample did. As expected, most alterations detected in plasma were also observed in tumor (Fig. 5 ), indicating that arm-level CNVs from plasma were reliable. An interesting phenomenon was that arm-level CNV events detected in tumor tissue were much more significant than that in plasma. This might be due to the low trace of circulating tumor DNA (ctDNA) released from tumors into plasma, and thus copy number changes on chromosomes may not be statistically significant and extraordinarily difficult to track in plasma. 6 ). We found that the healthy controls and CRC samples could be clustered respectively due to the similarity of chromosome instability in CRC.
All these results hinted that we might distinguish CRC patients from health control by scoring frequently impacted chromosome arms with optimized algorithm.
Individual sample prediction based on the SVM
Considering the low sensitivity of the regular z score in CRC diagnosis and the distribution pattern of arm-level CNVs in different chromosomes, we applied the SVM classifier to predict CRC patients based on the z score.
We randomly selected 40 samples to construct the training cohort, yielding a sensitivity of 95% and specificity of 100%. To validate the potential sensitivity and specificity of the SVM for discriminating CRC patients from healthy individuals using cfDNA, receiver operating characteristic (ROC) analysis was performed using the test set. Finally, SVM classifier prediction from 30 test samples yielded a sensitivity of 91.67% and specificity of 88.9%, with an area under the curve (AUC) of 0.8796 to detect CRC patients (see Fig. 7 and Table 3 ). In addition, our method performed well for the diagnosis of early CRC patients. All five CRC patients in stages I and II were detected, yielding a sensitivity of 100% for early CRC. 
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Discussion
We launched a pilot study of the use of arm-level CNVs to detect CRC and finally reached a satisfactory sensitivity of 100% for early CRC detection. This study is the first to apply a SVM classifier based on armlevel CNVs across the whole genome to detect CRC, especially at the early stage, via cfDNA in plasma. It's well believed that the occurrence and development of tumor is accompanied with somatic genetic alterations and epigenetic changes, including single nucleotide variation (SNV), Insertion and deletions (InDels), copy number variation (CNV), methylation alteration, virus infection and chromosome remodeling. These somatic changes occur at negligible frequencies in normal cell populations and therefore provide exquisitely specific biomarkers [22] . Circulating tumor DNA (ctDNA) is DNA fragments carrying tumor specific sequence alterations circulating plasma, representing a variable and generally small fraction of the total circulating free DNA (cfDNA) [23] . Many efforts have been put to detect somatic SNV and InDels in plasma for noninvasive assessment of cancer. Newman et al. claimed that their CAPPseq assay could be used to detect tumor-specific point mutations on selected driver genes in 100% of patients with stage II-IV NSCLC, but only in 50% of patients with stage I [24] . However, when CAPPseq is chosen as a screening technique, there are some disadvantages, including the low sensitivity for detection of early stage of cancer, difficulties on interpretation of uncertain somatic SNVs, as well as high cost for 10000× sequencing depth, The arm-level CNV detection by next-generation sequencing (NGS) in plasma requires less sequencing depth than SNV detection [25, 26] , detecting the aneuploidy of cfDNA in plasma is a potential method with high specificity and low cost. In this study, we showed that detection of chromosomal arm-level CNVs could be utilized as a screening method for CRC at a reagent cost of approximately $100. Using SVM classifier analysis, the sensitivity reached 91.7% with the specificity of 88.9%.
Some recent studies were also supported the applied plasma DNA-based CNV assay can be used in cancer detection. Leary et al. showed that detection of chromosomal alterations in plasma cfDNA with whole genome sequencing represents a useful method for non-invasive detection of human tumors. Furthermore, plasma aneuploidy score (PA score, based on the five chromosome arms with the highest absolute z score) were firstly introduced to improve sensitivity and specificity [12] . Li et al. detected plasma genomic abnormality in colon cancer with PGA-C score (Plasma Genomic Abnormality in CRC, similar to PA score, summing the most significant CNVs) and concluded that there were no significant differences in the PGA-C scores among healthy controls, patients with CRC stage I, CRC stage II as well as stage III. PGA score was statistically higher in stage IV CRC patients only [27] . In our study, we also evaluated the performance of PA score for cancer detection, as shown in Fig. 8 . Although the area under the curve (AUC) reached to 0.7322 and had significant difference (p = 0.0022), most of CRC samples could not be distinguished from healthy controls, giving similar results to Li's work. Based on these results, the trained SVM classifier we developed in this work was more feasible than the regular z score and PA score, especially for early CRC.
However, there are several limitations of our study. First, only 70 CRC patients and healthy volunteers were included and the sample size of early stage cancers was small. During the SVM classifier process, 40 samples were randomly selected as the training set and the remaining 30 were used as the test set in which there were only 5 early stage patients. The limited number of samples might make the compromising conclusion. Second, we did not take the classification of CRC into consideration. CRC can be classified into five types according to DNA microsatellite instability (MSI) or microsatellite stability (MSS) and CpG island methylation phenotype (CIMP): Type 1 (CIMP-high ⁄MSI-High ⁄ BRAF mutation), Type 2 (CIMP-high ⁄ MSI- classification, approximately 10-23% of CRC (type 1, 2 and 5 subgroups) could not be detected using CNV markers. In a future study, we will combine CNV and other markers, such as MSI, CIMP or BRAF mutation, to expand the coverage of CRC subtypes and hence improve sensitivity. In addition, considering the limited number of patients in this study, a multicenter study with a larger targeted cohort is needed to validate our results.
Collectively, we developed a novel method based on CNV from cfDNA to detect CRC patients from healthy individuals. The results of our method proved that CNV can be used as a tumor biomarker to screen early CRC with acceptable sensitivity and specificity. Subsequent clinical studies will employ larger cohorts to accurately determine the sensitivity and specificity of our method before translation to clinical applications.
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